BTG
Genetically Engineered Drugs
StartupBTG is a Be'er Tuvia-based startup in the Health Tech & Life Sciences sector, established in 1980. Genetically Engineered Drugs. The company has raised a total of $26.93M across 4 funding rounds, currently at the Acquired stage. Key investors include Ferring Pharmaceuticals. The company has 201-500 employees. Core technologies: Biologicals.
With $26.93M in total funding, BTG is a Acquired-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C business model. Product stage: Released. BTG has been acquired.
- StageAcquired
- ProductReleased
- ModelB2B2C
- Employees201-500
- HQBe'er Tuvia
- DistrictSouth District
- StatusAcquired
- Last Round$15M
- Ferring Pharmaceuticals
6 articles covered by sources including www.israelhayom.co.il,
www.themarker.com,
www.jpost.com,
www.timesofisrael.com,
www.globes.co.il.
What does BTG do?
Bio-Technology General Israel (BTG) is an integrated biopharmaceutical services company that develops and manufactures healthcare products derived from genetic engineering and biotechnology processes. BTGs Biolon, first introduced in 1993, is an injectable system containing 1% fermentation-derived sodium hyaluronate (NaHA) used as a viscoelastic aid in cataract and other ophthalmic surgeries. Euflexxa is a treatment to help relieve knee pain due to osteoarthritis (OA). It is used by thousands of people to help manage OA knee pain and stay active. Containing 1% fermentation-derived sodium hyaluronate, Euflexxa is intended for intra-articular injection into the knee. Developed in the 1980s, BTGs recombinant human growth hormone (somatropin for injection or hGH) first gained regulatory approval in 1988. It is identical to natural human growth hormone synthesized by the pituitary gland, and is used to treat Turner syndrome and growth hormone deficiency in children. BTG is a wholly owned subsidiary of Ferring Pharmaceuticals.
How much funding has BTG raised?
BTG has raised $26.93M in total funding across 4 rounds. The company is currently at the Acquired stage. Key investors include Ferring Pharmaceuticals.
What sector is BTG in?
BTG operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals, Healthcare, Patients.
Where is BTG located?
BTG is based in Be'er Tuvia, Israel, South District.